tbuckley/cabot-search huggingface dataset:
Expression of the murine plasma cell nucleotide pyrophosphohydrolase PC-1 is shared by human liver, bone, and cartilage cells. Regulation of PC-1 expression in osteosarcoma cells by transforming growth factor-beta.
Authors: R Huang, M Rosenbach, R Vaughn, D Provvedini, N Rebbe, S Hickman, J Goding, R Terkeltaub
Journal: Journal of Clinical Investigation (1994)

A bone and cartilage enzyme with both 5'-nucleotide phosphodiesterase I and nucleotide pyrophosphohydrolase (NTPPPH) activity modulates physiologic mineralization and pathologic chondrocalcinosis by generating inorganic pyrophosphate. We hypothesized that, as for alkaline phosphatase, expression of an NTPPPH gene can be shared by cells from bone, cartilage, and liver and by certain leukocytes. Recently, we demonstrated the hepatocyte and murine plasma cell membrane glycoprotein PC-1 to have both 5'-nucleotide phosphodiesterase I and NTPPPH activity. We detected polypeptides cross-reactive with PC-1 in human U20S osteosarcoma cells, articular chondrocytes, homogenized human knee cartilages, human knee synovial fluids, hepatoma cells, and murine plasmacytoma cells. Constitutive low abundance PC-1 mRNA expression was detected in U20S cells and chondrocytes by a nested RNA-PCR assay and by Northern blotting. TGF beta is known to substantially increase NTPPPH activity in primary osteoblast cultures. We demonstrated that TGF beta 1 increased NTPPPH activity and the level of PC-1 mRNA and immunoprecipitable [35S]-methionine-labeled PC-1 polypeptides in U20S cells. The identification of PC-1 as an NTPPPH expressed in cells derived from bone and cartilage may prove useful in furthering the understanding of the role of NTPPPH i n physiologic and pathologic mineralization.
A Case of Lipoatrophy With Lispro Insulin Without Insulin Pump Therapy
Authors: Alfonso Arranz, Victor Andia, Antonio López-Guzmán
Journal: Diabetes Care (2004)

Localized lipoatrophy occurring in the subcutaneous insulin injection area in diabetic patients was a phenomenon practically forgotten after the introduction of human insulin in medical practice. In recent years, there have been very few publications in relation to this matter.

Three cases of patients with type 1 diabetes who presented with subcutaneous localized lipoatrophy areas and who were in treatment with Lispro insulin were recently reported (1,2). The three patients used a continuous subcutaneous insulin infusion (CSII) system; therefore, the authors posed the doubt of whether such an administration system locally played a determinant role in the occurrence of subcutaneous localized lipoatrophy.

We present a case of localized lipoatrophy associated with treatment with Lispro insulin administered in a multiple dose regimen that disregards the role of CSII as a necessary factor for its genesis.

Our patient is a 35-year-old woman diagnosed in January of …
791. Unraveling Disease-Inducible Promoters from Gene Expression Profiling for Therapeutic Application in Arthritis
Authors: Jeroen Geurts, Onno J. Arntz, Miranda B. Bennink, Leo A. Joosten, Wim B. van den Berg, Fons A. van de Loo
Journal: Molecular Therapy (2006)

Currently, gene therapy in rheumatoid arthritis is predominantly based on viral transfer of a transgene under control of a constitutively active promoter, e.g. the CMV promoter. Although constitutive production of therapeutic proteins has shown efficacy in experimental arthritis models, production of excessive amounts of these biologicals may cause serious side effects. More ideally, the promoter activity must parallel the severity of inflammation, thereby providing auto-regulatory therapeutic protein expression. Previously, we have described inflammation-inducible upregulation of transgenes under control of a hybrid IL-1 enhancer/IL-6 (IL-1E/IL-6P) promoter in both the collagen type II- (CIA), and zymosan-induced arthritis (ZIA) model. However, the absolute protein level reached with the IL-1E/IL-6P promoter limited its application in arthritis utilizing the IL-1 receptor antagonist. Therefore, we designed a strategy to identify a new candidate promoter from gene expression profiling in murine synovial tissue that meets the following requirements: i) low basal activity, ii) inflammation-inducible, and iii) capable of high transgene expression.
OUTCOME IN RELATION TO ANTITHROMBOTIC THERAPY AFTER MYOCARDIAL INFARCTION AND PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
Authors: Gorav Batra, Leif Friberg, David Erlinge, Stefan James, Tomas Jernberg, Bodil Svennblad, Lars Wallentin, Jonas Oldgren
Journal: Journal of the American College of Cardiology (2015)
Adjusting diffusing capacity of the lung for carbon monoxide for haemoglobin level: Table 1–
Authors: Ming-Ju Tsai, Chih-Jen Yang, Jhi-Jhu Hwang, Ming-Shyan Huang
Journal: European Respiratory Journal (2013)

Adjusting diffusing capacity of the lung for carbon monoxide for haemoglobin levelTo the Editor:The joint statements on lung function testing by the American Thoracic Society (ATS)/European Respiratory Society (ERS) Task Force provided useful recommendations for standardisation of the tests in daily practice [1].However, the equations for adjusting diffusing capacity of the lung for carbon monoxide (DL,CO) for the haemoglobin (Hb) level (equations 13 and 14 in the original document) may be confusing [1].In daily clinical practice, instead of changing the predicted reference value, we tend to adjust the observed DL,CO value as if the patient had a normal Hb level [2][3][4].Therefore, as suggested by most guidelines [2, 4], we suggest new equations for adjustment, as shown in table 1.It is well known that anaemia decreases observed DL,CO by decreasing the area for diffusion due to a reduction in pulmonary capillary haemoglobin [1][2][3][4].For example, in our suggested equation for adult males and adolescents, a Hb level ,14.6 g?dL -1 makes (10.22+Hb)/(1.76Hb).1,making DL,CO adjusted for Hb .DL,CO observed to eliminate the effect of anaemia.This adjustment makes DL,CO more standardised for assessing pulmonary conditions.
Cost-Effectiveness of Statins Added to Aspirin Therapy
Authors: Mark K. Chelmowski
Journal: Annals of Internal Medicine (2006)

Letters1 August 2006Cost-Effectiveness of Statins Added to Aspirin TherapyMark K. Chelmowski, MDMark K. Chelmowski, MDFrom Advanced Healthcare, Milwaukee, WI 53209.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-145-3-200608010-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: Pignone and colleagues (1) concluded that adding a statin to aspirin therapy is cost-effective when the risk for coronary heart disease (CHD) is greater than 10%. In their model, the authors used a yearly statin cost of $730, which was the average of the Red Book costs for 10 mg of lovastatin and 10 mg of simvastatin.I find in my clinical practice that patients need higher doses of these drugs, more potent statins, or even a second lipid-lowering drug to reach the guidelines set by the National Cholesterol Education Program Expert Panel (2). These approaches are ...References1. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144:326-36. [PMID: 16520473] LinkGoogle Scholar2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97. [PMID: 11368702] CrossrefMedlineGoogle Scholar3. Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med. 2000;132:769-79. [PMID: 10819699] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Advanced Healthcare, Milwaukee, WI 53209.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics Lisa A. Prosser , Aaron A. Stinnett , Paula A. Goldman , Lawrence W. Williams , Maria G.M. Hunink , Lee Goldman , and Milton C. Weinstein Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis Michael Pignone , Stephanie Earnshaw , Jeffrey A. Tice , and Mark J. Pletcher Cost-Effectiveness of Statins Added to Aspirin Therapy Michael Pignone Metrics 1 August 2006Volume 145, Issue 3Page: 233KeywordsCholesterolCoronary heart diseaseDrugsMotivationRisk managementStatinsTreatment guidelines ePublished: 1 August 2006 Issue Published: 1 August 2006 Copyright & PermissionsCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Scalp ringworm in south-east London and an analysis of a cohort of patients from a paediatric dermatology department
Authors: L.C. Fuller, F.C. Child, G. Midgley, E.M. Higgins
Journal: British Journal of Dermatology (2003)

Summary Background Scalp ringworm or tinea capitis has become an increasingly important public health issue in the past decade in Great Britain. Recently, certain dermatology departments in London have seen a large increase in tinea capitis in all its forms. Objectives The aim of this paper is to present the detailed analysis of a cohort of 277 patients with tinea capitis seen during a 2-year period together with the latest local figures of tinea capitis cases from an inner city paediatric dermatology service. Methods Demographic, clinical and laboratory data were collected prospectively over 2 years from all cases of ringworm in patients seen in a paediatric clinic specially set up for scalp problems. Results Sixty-two per cent of 277 cases of scalp ringworm were caused by Trichophyton tonsurans, occurring mainly (91%) in patients with Afro-Caribbean hair type, more often in boys (68%), and in the 3–8 year olds (70%). Only 7% of the patients had received appropriate treatment with oral griseofulvin. An additional 156 cases from the general paediatric dermatology clinic showed 91%T. tonsurans infections. Conclusions The prevalence of scalp ringworm appears to be reaching epidemic proportions in certain areas that include south-east London. The clinical problem is not yet well recognized by local general practitioners.
Increased Plasma Natriuretic Peptide Levels Reflect Symptom Onset in Aortic Stenosis
Authors: Ivor L. Gerber, Ralph A.H. Stewart, Malcolm E. Legget, Teena M. West, Renelle L. French, Timothy M. Sutton, Timothy G. Yandle, John K. French, A. Mark Richards, Harvey D. White
Journal: Circulation (2003)

Background— The onset of symptoms is a critical point in the natural history of aortic stenosis and the cardinal indication for valve replacement. This study assessed the associations between natriuretic peptide levels, disease severity, and cardiac symptoms in aortic stenosis. Methods and Results— Seventy-four patients with isolated aortic stenosis underwent independent assessment of symptoms, transthoracic echocardiography, and measurement of plasma levels of atrial natriuretic peptide, brain natriuretic peptide (BNP), and N-BNP. Natriuretic peptide levels were also measured in 100 clinically normal control subjects. The aortic valve area was smaller in symptomatic patients (n=45) than in asymptomatic patients (n=29; mean, 0.71±0.23 cm 2 and 0.99±0.31 cm 2 , respectively; P &lt;0.0001). Plasma natriuretic peptide levels were higher in symptomatic patients than in asymptomatic patients (for N-BNP: median, 112 versus 33 pmol/L; interquartile range, 70 to 193 versus 16 to 58 pmol/L, respectively; P =0.0002). After adjustment for age, sex, serum creatinine, aortic valve area, and left ventricular ejection fraction, N-BNP levels were 1.74 times higher (95% confidence interval, 1.12 to 2.69) for symptomatic than asymptomatic patients with aortic stenosis ( P =0.014). Natriuretic peptide levels increased with the New York Heart Association class (for N-BNP median values were 13, 34, 105, and 202 pmol/L for normal control subjects, class I, class II, and class III/IV patients, respectively; interquartile ranges for the same patients were 8 to 21, 16 to 58, 57 to 159, and 87 to 394 pmol/L; P &lt;0.0001). Similar associations were observed for BNP and atrial natriuretic peptide. Conclusions— Plasma natriuretic peptide levels are elevated in symptomatic patients with aortic stenosis. Measurement of natriuretic peptides may complement clinical and echocardiographic evaluation of patients with aortic stenosis.
Tc-99m Sestamibi Uptake by Parathyroid Carcinoma
Authors: DWIGHT M. ACHONG, ELIZABETH OATES
Journal: Clinical Nuclear Medicine (1995)

Tc-99m sestamibi (MIBI) is increasingly used for the preoperative localization of parathyroid adenoma. As experience is gained with this radiopharmaceutical, instances of uptake by non-adenomas will be encountered. A case of focal Tc-99m MIBI uptake by parathyroid carcinoma mimicking parathyroid adenoma is presented.
Laryngeal Edema Associated With Sickle β-Thalassemia Disease
Authors: Gary S. Greene
Journal: JAMA (1982)

SICKLE β-thalassemia, a hemoglobinopathy closely related to sickle cell disease, demonstrates vaso-occlusive phenomena similar to homozygous sickle cell anemia. We describe a patient who experienced severe laryngeal edema secondary to sludging of sickled RBCs (drepanocytes) in the capillaries and lymphatic channels in the laryngeal microvasculature. To our knowledge, this finding has not been previously reported in the literature. <h3>Report of a Case</h3> A 29-year-old man with known sickle β-thalassemia disease came to the emergency room with acute dyspnea on June 26, 1980, and was admitted to the hospital. Indirect laryngoscopy showed marked edema of the left arytenoid mucosa and false vocal cord. The true vocal cord was obscured by a ventricular band. The glottic opening was diminished on deep inspiration. The right side of the larynx, however, appeared normal. A regimen of 100 mg of hydrocortisone every six hours produced some abatement of the patient's symptoms. Two days after admission,
Should UK membership exams be held overseas? Yes
Authors: G. Muir, J. Thacker
Journal: BMJ (2011)

<b>Graeme Muir</b> and <b>Justin Thacker </b>believe that UK professional qualifications can help other countries improve training and standards, but <b>Delan Devakumar</b> and <b>Kate Mandeville </b>(doi:10.1136/bmj.d4560) argue that they lack local relevance
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
Authors: Maite P. Quiroga, Kumudha Balakrishnan, Antonina V. Kurtova, Mariela Sivina, Michael J. Keating, William G. Wierda, Varsha Gandhi, Jan A. Burger
Journal: Blood (2009)
Mediation of increased vascular permeability after complement activation. Histamine-independent action of rabbit C5a.
Authors: T J Williams, P J Jose
Journal: The Journal of Experimental Medicine (1981)

Intradermal injection of zymosan into nonsensitized rabbits induces plasma exudation, which is dependent on two mediators: C5a generated in extravascular tissue fluid and a vasodilator prostaglandin generated from substrates localized in cell membranes. This relationship between the complement system and the prostaglandin synthesis system had not previously been explored, and complement activation has generally been associated with increased vascular permeability via histamine release. We report that C5a increases vascular permeability by a mechanism that is not dependent on histamine release; however plasma exudation is virtually undetectable in the absence of a vasodilator substance. Because the permeability-increasing activity is stable in plasma, analogy with other species suggests that the activity is a result of C5a devoid of its carboxyl terminal arginine (C5a des Arg). This relates the observed permeability-increasing activity with effects on leukocytes rather than effects as an anaphylatoxin.
Nutrition and Hyperactivity
Authors: Gilbert B. Forbes
Journal: JAMA (1982)

Nutrition is in the air these days. Unsatisfied with the victory over specific nutritional deficiencies (rickets, scurvy, and pellagra are largely diseases of the past in Western society), the public and the medical profession are concentrating on new nutritional horizons. One such is the hyperactive child, who in previous generations was considered incorrigible, but today, through the action of learned committees, has been designated as having an "attention-deficit disorder."1 Such children, most of whom are boys, have always presented a problem to parents and schoolteachers, a problem so seemingly insoluble that any proposed solution, be it drugs or diet, is immediately greeted with enthusiasm. I first met Benjamin Feingold, MD, when he spoke at the June 1973 meeting of the American Medical Association in Chicago. He espoused his theory with great vigor and little documentation. Then came his book,<sup>2</sup>which immediately attracted wide attention, for in it he stated that
QUININ IN PNEUMONIA.
Authors: A. S. v. MANSFELDE
Journal: JAMA (1906)

Under the caption, "Quinin in Pneumonia," inThe Journal, March 3, Dr. J. B. Cutter complains that Dr. W. J. Galbraith claims originality in the use of large doses of quinin, when Dr. A. J. Giesy pursued that course in 1894. Permit me to direct attention to page 165, vol. v, Ziemsen's "Cyclopedia of the Practice of Medicine," published in 1875, a translation of Prof. Theodore Juergensen's classic article on "Croupous Pneumonia," the disease under consideration. There he says: "When the fever is intense, 77 grains may be given to a strong adult and 15 grains to a child under 1 year, always in one dose. I have repeatedly used both of these amounts. I have acquired my experience by gradually increasing doses, and I have never seen any harm done; in fact, it is my firm belief that even these are not the extreme limits as to quantities." Personally
Alteration of laboratory findings after radiofrequency ablation of hepatocellular carcinoma: relationship to severity of the underlying liver disease and the ablation volume
Authors: Sang-Wook Shin, Woo Kyoung Jeong, Sanghyeok Lim, Yongsoo Kim, Jinoo Kim
Journal: Clinical and Molecular Hepatology (2015)

Background/Aims To investigate sequential changes in laboratory markers after radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) and the relationship of these changes to the severity of the underlying liver disease. Methods This retrospective analysis included 65 patients (44 males, 21 females) who underwent RFA of HCC. Hematologic and biochemical markers were assessed at the pre-RFA period and 1 day, 2-3 days, and 1-2 weeks after RFA. We classified the subjects into two groups: Child-Pugh A (n=41) and Child-Pugh B (n=24). The ablative margin volume (AMV) of each patient was measured. We analyzed the changes in laboratory profiles from the baseline, and investigated whether these laboratory changes were correlated with the AMV and the Child-Pugh classification. Results Most of the laboratory values peaked at 2-3 days after RFA. AMV was significantly correlated with changes in WBC count, hemoglobin level, and serum total bilirubin level (Pearson's correlation coefficient, 0.324-0.453; P<0.05). The alanine aminotransferase (ALT) level varied significantly over time (P=0.023). Conclusions Most of the measured laboratory markers changed from baseline, peaking at 2-3 days. The ALT level was the only parameter for which there was a significant difference after RFA between Child-Pugh A and B patients: it increased significantly more in the Child-Pugh A patients. Keywords: Alanine aminotransferase; Child-Pugh class; Hepatocellular carcinoma; Leukocytosis; Radiofrequency ablation
Hepatocellular Carcinoma and a Variant Alkaline Phosphatase
Authors: K. HIGASHINO
Journal: Annals of Internal Medicine (1975)

Four patients with hepatocellular carcinoma had a variant alkaline phosphatase that resembles the placental D-variant but is different from it in electrophoretic mobility, pH optimum, heat stability, and inhibition by phosphate. The appearance of this enzyme has been specific to hepatocellular carcinoma. Its prevalence was about 30%, while that of another marker protein, alpha-fetoprotein was 77%. The occurrence of this enzyme in serum of patients with hepatoma was, accordingly, independent of the serum alpha-fetoprotein concentration, and also independent of the appearance of the Regan or the Nagao isoenzymes and of the serum alkaline phosphatase activity. Patients with the enzyme had a massive type of hepatocellular carcinoma with grade III differentiation by Edmondson's classification. The detection of this enzyme in serum may be of help in confirming the diagnosis of hepatoma.
Paracetamol and Renal Damage
Authors: O. M. Edwards, P. Edwards, E. C. Huskisson, R. T. Taylor
Journal: BMJ (1971)

Renal function was assessed in 18 patients who had consumed 2 to 30 kg of paracetamol. No relationship was found between the total amount of paracetamol taken and any aspect of renal function studied. No patient had clinically significant renal impairment. Thirteen of the patients showed no significant deterioration of renal function over a period of about one year during which they consumed an additional mean 2 kg of paracetamol.
Fireworks on Hudson
Authors: Janet M. Torpy
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chess and the Computer
Authors: Marshall E. Deutsch
Journal: JAMA (1979)

<h3>To the Editor.—</h3> I read with great interest the letter on "Chess and the Computer." How ironic that Dr Diosy was not aware that David Levy, the international chess master from Scotland, recently defeated a computer programmed by American experts and that he won his wagers of $1,000 and £500 on this issue.<sup>1</sup> I cannot but agree with William H. Crosby, MD, that "the algorithm, like chess, is clean, elegant, intellectual, and knowable. On the other hand, life is a mess and so is the practice of medicine."